{"database": "lobbying", "table": "lobbying_activities", "rows": [[2461234, "5f6ebe1e-a315-4a01-b77a-270334b2a0b1", "Q2", "JAMES EDWARDS", 401027897, "CONSERVATIVES FOR PROPERTY RIGHTS", 2020, "second_quarter", "CPT", "S. 2082/H.R. 3666 (STRONGER Patents Act)\nTrade-related intellectual property policy/practices/encroachment by foreign countries/companies against U.S. competitiveness interests - China, Committee on Foreign Investment in the United States review of Chinese acquisitions and joint ventures, United States-Mexico-Canada Agreement IP chapter, International Trade Commission exclusion of U.S. patent-infringing imports, ITC baseband chip set patent infringement remedy, intellectual property exclusivity and protections in trade agreements\nPiracy of online and streaming copyrighted content\nCompulsory licensing - S. 377/H.R. 1046 (Medicare Negotiation and Competitive Licensing Act), S. 102/H.R. 465 (Prescription Drug Price Relief Act), S. 977 (Transparent Drug Pricing Act)\nNIST Return on Investment Initiative for Unleashing American Innovation\nS. 344/H.R. 990 (Hatch-Waxman Integrity Act)\nFTC/patent licensing as exclusive property right\nBayh-Dole Act/technology transfer, march-in rights\nProcedural and evidentiary standards used at Patent Trial and Appeal Board\nPTO patentable subject matter eligibility guidance\nSection 101 patentable subject matter reform\nInjunctive relief from willful infringement\nDOJ-DOC withdrawal of 2013 Policy Statement on Remedies for Standards-Essential Patents Subject to Voluntary F/RAND Commitments\nS. 1273/H.R. 2426 (Copyright Alternative in Small-Claims Enforcement (CASE) Act)\nS. 1416 (Affordable Prescriptions for Patients Act)\nObviousness/No Combination Drug Patents Act\nH.R. 4398/H.R. 5133 (Affordable Prescriptions for Patients Through Promoting Competition Act)\nH.R. 3991 (Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act)\nH.R. 5478 (Inventor Rights Act)\nPatent licensing/standards-essential patents/U.S. technological leadership in 5G and other technologies/economic and national security implications\nDOJ-PTO-NIST 2019 revised Joint Statement on Remedies for Standards-Essential Patents Subject to Voluntary F/RAND Commitments\nEfficient infringement\nDigital Millennium Copyright Act modernization\nPatent Trial & Appeal Board Covered Business Methods program\nPTAB Rules of Practice for Instituting on All Challenged Patent Claims and All Grounds and Eliminating the Presumption at Institution Favoring Petitioner as to Testimonial Evidence (Docket No. PTO-P-2019-0024)\nS. 3630 (Facilitating Innovation to Fight Coronavirus Act)\nDenial of rights of exclusivity for COVID-19-related innovations\nH.R. 7366 (Restoring Americas Leadership in Innovation Act)", "Council on Environmental Quality (CEQ),Environmental Protection Agency (EPA),Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Patent & Trademark Office (PTO),SENATE", 10000, null, 0, 0, "2020-07-06T09:07:03.570000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2461234"], "units": {}, "query_ms": 23.96958298049867, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}